

1 The Value of Rapid Antigen Tests to Identify Carriers of Viable SARS-CoV-2

2 **Short title:** Antigenic tests to identify patients with viable SARS-CoV-2

3 **Elena V. Shidlovskaya¹, Nadezhda A. Kuznetsova¹, Elizaveta V. Divisenko¹, Maria**
4 **A. Nikiforova¹, Andrei E. Siniavin^{1,2}, Daria A. Ogarkova¹, Aleksandr V. Shagaev⁴,**
5 **Maria A. Semashko¹, Artem P. Tkachuk¹, Olga A. Burgasova^{1,3}, Vladimir A.**
6 **Gushchin^{1,5,*}**

7 ¹ N.F. Gamaleya National Research Center for Epidemiology and Microbiology,
8 Ivanovsky Institute of Virology, Ministry of Health of the Russian Federation, 123098,
9 Moscow, Russia

10 ² Department of Molecular Neuroimmune Signalling, Shemyakin-Ovchinnikov Institute of
11 Bioorganic Chemistry, Russian Academy of Sciences, 117997, Moscow, Russia

12 ³ Peoples Friendship University of Russia (RUDN) University, 117198, Moscow, Russia

13 ⁴ Moscow Healthcare Department, 127006 Moscow, Russia

14 ⁵ Department of virology, Lomonosov Moscow State University, 119991, Moscow,
15 Russia

16 * Address for correspondence: Vladimir A. Gushchin wowaniada@gmail.com

17

18 **Abstract**

19 The search for effective methods to detect patients who excrete a viable virus is
20 one of the urgent tasks of modern biomedicine. In the present study, we examined the
21 diagnostic value of two antigen tests BIOCREDIT COVID-19 Ag (RapiGEN Inc., Korea)
22 and SGTI-flex COVID-19 Ag (Sugentech Inc., Korea) for their diagnostic value in
23 identifying patients who excrete viable SARS-CoV-2. As part of the study, we examined
24 samples from 106 patients who had just been admitted to the hospital, who had
25 undergone quantitative RT-PCR and assessment of viability of SARS-CoV-2 using cell
26 culture. Sensitivity was 0.786 (0.492–0.953) for SGTI-flex COVID-19 Ag and 1 (0.768–
27 1) for Biocredit COVID-19 Ag. Specificity of rapid tests was significantly higher than that
28 of RT-PCR and was 0.663 (0.557–0.758) and 0.674 (0.568–0.768) for SGTI-flex
29 COVID-19 Ag and Biocredit COVID-19 Ag versus 0.304 (0.213–0.409) obtained for
30 PCR. Thus, for tasks of identifying viable SARS-CoV-2 during screening of conditionally
31 healthy people, as well as monitoring those quarantined, rapid tests show significantly
32 better results.

33

34

35 Introduction

36 The SARS-CoV-2 virus pandemic has been a major global problem for over a
37 year. The lack of effective and widely available means of prevention and etiologic
38 treatment has led to a situation where wearing a mask and social distancing [1] remain
39 the primary ways to lift pressure off the healthcare system, allowing the most severe
40 COVID-19 patients to receive timely and necessary care in medical institutions, while
41 patients with mild to moderate course are forced to remain on lockdown. At the same
42 time, massive restrictions significantly reduce economic activity and, as a result,
43 increase the risks of slowing down economic growth [2].

44 The main problem of monitoring and surveillance of SARS-CoV-2 is the ability of
45 the virus to spread from asymptomatic patients several days before any symptoms
46 occur [3], [4]. Moreover, contribution to the transmission of the virus from asymptomatic
47 patients and from patients before the onset of symptoms is a significant problem both
48 for the spread of the virus and for accounting for COVID-19 cases [5].

49 The recent successful launch of SARS-CoV-2 vaccines gives hope for an early
50 reduction of the pandemic and a return to pre-quarantine living conditions [6], [7], [8],
51 [9]. All major vaccines ensure a convincing level of protection (over 90%) in the short
52 term and reliable protection against the severe course of COVID-19. At the same time,
53 the results of the study do not guarantee protection of those vaccinated from
54 subsequent infection with SARS-CoV-2, an asymptomatic course of the disease, which
55 means that further participation of those vaccinated in the spread of the virus has yet to
56 be investigated. The emergence of new strains capable of partial or complete escape
57 from the neutralizing effect of antibodies poses the most danger during prolonged mass
58 vaccination [10], [11], [12].

59 Detection of viral RNA does not always mean that a person is an infection carrier
60 and spreader. However, in the light of objective epidemic control, it is important to
61 specifically identify carriers of SARS-CoV-2. Timely and prompt identification of the
62 spreaders of infection and their isolation can improve the effectiveness of anti-epidemic
63 measures. Virus viability, as evaluated using cell culture, for samples with a viral load of
64 30 cycles (about 10^5 – 10^6 GE/mL and below), in RT-PCR tests, is only 3% [13]. It is
65 obvious that the use of methods to assess virus viability using cell culture is unsuitable

66 for mass use due to the complexity of the procedure and the high cost. This requires the
67 search for new simpler methods to identify the spread of the infection.

68 Rapid antigen tests, which have recently become widespread for the diagnosis of
69 COVID-19, in contrast to PCR, detect SARS-CoV-2 antigens, which, like RNA, comprise
70 viral particles and are produced in infected cells during the life cycle of the virus. The
71 disadvantage of antigen tests is their lower sensitivity compared to RT-PCR. According
72 to the results of Cochrane meta-analysis, sensitivity varies greatly: average sensitivity is
73 56.2% (95% CI, from 29.5 to 79.8%), average specificity is 99.5% (95% CI, from 98.1%
74 to 99.9%; based on 8 experiments in 5 studies on 943 samples) [14]. At the same time,
75 the definitive advantage of rapid antigen tests is the significantly less laborious process
76 and the ease of learning the procedure, allowing to use the test at home as Point of
77 Care (POC) testing. The time it takes to obtain the result is also crucial, which can be as
78 low as 5 minutes. Moreover, rapid antigen tests are not susceptible to contamination
79 with amplification products, characteristic of nucleic acid analysis methods, which
80 reduces the likelihood of a false positive result.

81 To date, there are no data on the effectiveness of rapid antigen tests for
82 identification of patients excreting viable SARS-CoV-2. In this paper, we describe
83 results of the pilot study of two rapid antigen tests BIOCREDIT COVID-19 Ag (RapiGEN
84 Inc., Korea) and SGTI-flex COVID-19 Ag (Sugentech Inc., Korea) for their value in
85 identifying patients excreting viable SARS-CoV-2. As part of the study, we examined
86 samples from 106 patients who had just been admitted to the hospital, who had
87 undergone two rapid tests: quantitative RT-PCR and viability assessment of SARS-
88 CoV-2 using susceptible cell culture 293T/ACE2. Samples were collected from January
89 25, 2021 to February 8, 2021 at an infectious diseases hospital in Moscow.

90 **Results**

91 *Study design*

92 To investigate the ability of rapid antigen tests to identify patients who excrete
93 viable SARS-CoV-2, it was planned to include primarily patients with suspected COVID-
94 19 newly admitted to the hospital. Participants were admitted to the hospital on 2 to 10
95 days from the onset of symptoms. The main symptoms were fever, dry cough, chest

96 pain and discomfort, shortness of breath, loss of smell and taste. All included patients
97 had CT signs of lung damage. The study included 106 patients aged 28 to 95 years
98 (mean age 67.67), including 53 women (mean age 68.45) and 53 men (mean age
99 66.89) (Appendix Table 1).

100

101 *Analytical characteristics of antigen tests compared to RT-PCR*

102 Result of PCR tests of smears from 106 patients was positive in 73.58% patients
103 (78 people). The viral load was determined for all positive samples (Appendix Tables 1,
104 2 and 3), which ranged from 88 to 3.5×10^8 GE/mL (median 4.6×10^4). The SGTI-flex
105 COVID-19 Ag rapid test identified 41 of 78 positive samples. Sensitivity of SGTI-flex
106 COVID-19 Ag was 0.526 (95% confidence interval 0.409–0.6399), specificity was 0.964
107 (0.817–0.999) (Table 1). In turn, the Biocredit COVID-19 Ag rapid test identified 44 of 78
108 positive samples. For the Biocredit COVID-19 Ag test, sensitivity was 0.564 (0.447–
109 0.676) and 1.000 (0.877–1.000), respectively. There was no significant differences
110 between the analytical characteristics of the tests ($p = 0.8026$, McNemar's test with
111 Edwards continuity correction).

112 **Table 1 – Assessment of sensitivity and specificity of rapid tests compared to RT-**
113 **PCR**

SGTI-flex COVID-19 Ag			Biocredit COVID-19 Ag		
PCR result	negative	positive	PCR result	negative	positive
negative	27	1	negative	28	0
positive	37	41	positive	34	44
Sensitivity	52.56%		Sensitivity	56.41%	
Specificity	96%		Specificity	100%	

114


115 For samples with a higher viral load, the sensitivity of tests was higher (Appendix
116 Table 2) and starting from a viral load of 1.02×10^5 ($\log_{10} = 5.0086$) for SGTI-flex
117 COVID-19 Ag and 4.74×10^4 ($\log_{10} = 4.6758$) for RapiGen Biocredit COVID-19 Ag, did
118 not differ statistically from the results of PCR tests at a significance level of 0.01 ($p =$

119 0.01333, McNemar's test with Edwards continuity correction). P-value only increased
120 with further increase in viral load.

121 To determine the analytical threshold of sensitivity with respect to the antigen in
122 virions of the culture fluid, we conducted a model experiment, when the culture fluid with
123 a known virus titer was used to assess the analytical sensitivity of rapid tests in the
124 range from 10^2 to 10^8 GE/mL, using an interval of one order of magnitude. Both tests
125 showed the detection limit at a virus titer of 10^6 GE/mL (10^5 GE/test), which
126 corresponded to 4×10^5 TCID₅₀/mL or 4×10^4 TCID₅₀/test. There was no statistically
127 significant difference in analytical characteristics depending on the day from the onset of
128 the disease (p-value = 0.2356 for SGTI-flex COVID-19 Ag, p-value = 0.8581 for
129 RapiGen Biocredit COVID-19 Ag with Fisher's exact test), which is not surprising given
130 that there were high-load patients on each day (Appendix Table 3).

131 *Analytical characteristics of antigen tests for viability*

132 All samples were evaluated for viability of SARS-CoV-2 virus using a sensitive
133 cell culture. Viability was assessed using the 293T/ACE2 cell line with stable expression
134 of the human ACE2 receptor. For samples with a cytopathogenic effect (CPE), RT-PCR
135 was performed to confirm that the CPE was caused by SARS-CoV-2 and not by other
136 infectious agents. Comparison of groups of samples with viable and non-viable viral
137 load measured by quantitative PCR showed a significant difference (p<0.0001, p-value
138 calculated using the Mann–Whitney test) (Fig. 1).



139

140 **Figure 1.** SARS-CoV-2 viral load in viable versus non-viable samples. Results are
141 represented by a box plot: horizontal lines – medians; boxes – interquartile range;
142 whiskers – min-max (p-value calculated using Mann–Whitney test)

143 Viability was shown only by samples with a viral load of 7.3×10^4 (GE/mL) and
144 higher (Fig. 1 and Table 2). However, not all samples with such a load remained viable.
145 Rapid tests were able to give a positive result on samples with median values of
146 5.72×10^4 and 3.78×10^4 (GE/mL) for Biocredit COVID-19 Ag and SGTI-flex COVID-19
147 Ag, respectively. However, a positive result was also obtained for a number of samples
148 with a load below 10^4 (GE/mL). It is not clear whether this is related to how the material

149 was collected for three different tests or the presence in some biological samples of a
 150 disproportionate amount of antigen in relation to viral RNA.

151 **Table 2 – Viral load (GE/mL) depending on viability and rapid test result**

Viral load (GE/mL)				
quantitative real-time RT-PCR				
value	Number of positive tests	Viral load (mean)	range	median
Successful isolation	14	4.71×10^7	$7.30 \times 10^4 - 3.50 \times 10^8$	1.03×10^6
Unsuccessful isolation	64	8.93×10^5	$89.00 - 2.56 \times 10^7$	2.26×10^4
BIOCREDIT COVID-19 Ag				
Successful isolation	14	4.71×10^7	$7.30 \times 10^4 - 3.50 \times 10^8$	1.03×10^6
Unsuccessful isolation	30	1.87×10^6	$89.00 - 2.56 \times 10^7$	5.72×10^4
RT-PCR “+”, antigen test “-”	34	2.87×10^4	$1.77 \times 10^2 - 1.46 \times 10^5$	9.85×10^3
SGTI-flex COVID-19 Ag				
Successful isolation	11	5.97×10^7	$7.30 \times 10^4 - 3.50 \times 10^8$	1.09×10^6
Unsuccessful isolation	30	1.40×10^6	$89.00 - 2.56 \times 10^7$	3.78×10^4
RT-PCR “+”, antigen test “-”	37	4.87×10^5	$1.77 \times 10^2 - 1.31 \times 10^7$	1.87×10^4

153 Overall, out of 106 samples, viable virus was detected in 14 patients,
 154 representing 13.2% of all participants. Using these samples, SGTI-flex COVID-19 Ag
 155 gave 11 (78.6%) positive results, while Biocredit COVID-19 Ag gave 14 (100%) positive
 156 results (Table 3). As a result, the sensitivity of antigen tests was 0.786 (0.492–0.953) for
 157 SGTI-flex COVID-19 Ag and 1 (0.768–1) for Biocredit COVID-19 Ag. Specificity was
 158 0.663 (0.557–0.758) and 0.674 (0.568–0.768) for SGTI-flex COVID-19 Ag and Biocredit
 159 COVID-19 Ag, respectively. For RT-PCR, the sensitivity was 1 (0.768–1), while the
 160 specificity was 0.304 (0.213–0.409).

161 **Table 3 – Assessment of sensitivity and specificity of rapid tests for viability**

	SGTI-flex COVID-19 Ag		Biocredit COVID-19 Ag		quantitative real-time RT-PCR	
	Positive	Negative	Positive	Negative	Positive	Negative
Viable virus	11	3	14	0	14	0
No viable virus	31	61	30	62	64	28
	Sensitivity 0.786 (0.492– 0.953)	Specificity 0.663 (0.557– 0.758)	Sensitivity 1 (0.768– 1)	Specificity 0.674 (0.568– 0.768)	Sensitivity 1 (0.768– 1)	Specificity 0.304 (0.213– 0.409)

162
 163 Comparing analytical characteristics of the tests for viability of the virus, it can be
 164 observed that the rapid tests are indistinguishable from each other (p-value = 0.4533,
 165 McNemar’s test with Edwards continuity correction), but they differ significantly from RT-
 166 PCR (p-value = 2.546e-06 for SGTI-flex COVID-19 Ag, p-value = 1.519e-08 for
 167 Biocredit COVID-19 Ag, McNemar test with Edwards continuity correction).

168 As the viral load increased, the sensitivity of the tests for viral viability increased
 169 and, starting from a viral load of 6.27E+04 (log10 = 4.7973) for SGTI-flex COVID-19 Ag
 170 and 5.11E+05 (log10 = 5.7084) for RapiGen Biocredit COVID-19 Ag, did not statistically

171 significantly differ from the possibility of successful isolation of a viable virus at a
172 significance level of 0.01 ($p = 0.01529$ and $p = 0.01333$, respectively).

173 There were no statistical differences in the analytical characteristics of rapid tests
174 depending on the day of the disease (p -value = 0.5292 for SGTI-flex COVID-19 Ag,
175 0.4108 for RapiGen Biocredit COVID-19 Ag using Fisher's exact test). At the same time,
176 the number of cases of successful isolation of a viable virus also did not statistically
177 differ at different time intervals of the disease, which is probably due to the limited
178 follow-up period and the use of only one sample from each patient.

179 **Discussion**

180 Prompt identification of carriers of the viable SARS-CoV-2 virus and their timely
181 isolation from the society is the most important step in containing a pandemic. Mass
182 screening, in turn, is limited by access of the population to laboratory testing, which in
183 the case of PCR is limited by the capabilities of laboratories. In this regard, many states
184 are adopting new approaches, whereby samples are pooled to increase the amount of
185 PCR tests [15], [16], [17], [18].

186 An alternative to using PCR laboratories is to use rapid antigen tests, including
187 for home use. In December 2020, the FDA for the first time authorized home use of an
188 antigen test to detect the virus [19]. There is no doubt that moving in this direction can
189 significantly improve access to testing. Evaluation of cost-effectiveness of mass
190 screening shows that in the case of, for example, the USA, the most optimal strategy is
191 weekly testing and two-week isolation of the infected person or monthly testing with
192 weekly isolation for scenarios of rapid ($Re = 2.2$) and slow ($Re = 1.2$) epidemic,
193 respectively [20]. The important point is that the use of antigen tests can significantly
194 increase the effectiveness of regular mass testing.

195 Recommendations regarding self-isolation and lockdown deserve special
196 attention. The existing WHO recommendations prescribe to revoke termination of
197 isolation for patients with manifest forms 13 days after the onset of symptoms, provided
198 that in the last 3 days the person did not experience any characteristic symptoms of the
199 disease, as well as 10 days after a positive PCR result for asymptomatic cases [21].
200 Those who have come into contact with a person with a confirmed diagnosis of COVID-

201 19 are also prescribed a 14-day quarantine, however testing during the quarantine or
202 upon its termination is not mandatory. Currently such a strategy is subject to serious
203 scientific criticism [22], [23]. Re-testing at the beginning of quarantine and upon its
204 termination, but with a shorter time spent in isolation, as well as daily testing instead of
205 quarantine, according to the results of a mathematical model, can be more effective in
206 protecting against the spread of the infection after the quarantine is over. An additional
207 benefit of a shorter quarantine is that the person returns to work faster, which reduces
208 the economic damage of the pandemic lock down. It is worth noting that for the
209 purposes of mathematical modeling, a patient with a positive test result is considered
210 potentially infectious to others. In this connection, using tests that improve the accuracy
211 of the evaluation of the number of persons excreting the virus will allow to further
212 improve the effectiveness of monitoring.

213 WHO notes that studies to evaluate the viability of the virus in patient samples
214 are currently very limited. Viable virus was excreting in persons without symptoms, in
215 patients with mild to moderate course of COVID-19 for 8–9 days after the onset of
216 symptoms, and for a longer time period in critical patients [21]. However, a meta-
217 analysis of the results of isolation of RNA and the viable virus extraction shows that
218 although SARS-CoV-2 RNA is excreted for several weeks, viable virus is not detected
219 already after 9 days [24]. Thus, given the significant difference in the dynamics of
220 isolation of RNA and the viable virus, there is now the need to look for tests that allow to
221 identify persons who excrete viable virus while minimizing the likelihood of a false-
222 positive result in patients who no longer excrete viable virus. This will minimize the
223 amount of persons quarantined, reducing the negative economic damage of the
224 pandemic. It also allows epidemiological services to focus on patients who are the real
225 sources of infection spread. In this study, we investigated the value of antigen tests for
226 identifying carriers of a viable virus.

227 We examined samples from 106 patients admitted to a hospital in Moscow. The
228 study included only those patients who had experienced first symptoms no earlier than
229 10 days before. All samples, in addition to being used for the two tests, were also used
230 for quantitative PCR and assessment of viral viability using cell culture. Of 106 samples,
231 78 (73.58%) were PCR-positive. This is significantly higher than previously published

232 data with similar clinical setting [25]. This is probably due to a difference in design, as
233 for the purposes of this study, we searched for patients who had just been admitted to
234 the hospital, while the other studies did not make such a distinction [26], [27], [28].

235 Data of quantitative PCR are of particular interest. The viral load was determined
236 for all PCR-positive samples and it was found that it varied greatly, from 88 to 3.5×10^8
237 GE/mL (median 4.6×10^4). In terms of viral load, samples that showed viability were
238 significantly different from the rest ($p < 0.0001$, the p-value was calculated using the
239 Mann–Whitney test). For all 14 samples that showed viability, the viral load was at least
240 7.3×10^4 (GE/mL). And although not all samples with a similar load or higher showed
241 viability, it is important that a cut-off quantitative threshold, after which the probability of
242 the virus remaining viable is greatly reduced, can be established experimentally.

243 Standard evaluation of analytical characteristics of rapid tests showed that,
244 relative to RT-PCR, their diagnostic characteristics were close to the mean values
245 published for the Cochrane meta-analysis [14]. For the SGTI-flex COVID-19 Ag test,
246 sensitivity was 0.526 (95% confidence interval 0.409–0.6399), specificity was 0.964
247 (0.817–0.999). For the Biocredit COVID-19 Ag test, sensitivity and specificity were
248 0.564 (0.447–0.676) and 1.000 (0.877–1.000), respectively. No significant differences
249 were found between tests ($p = 0.8026$). Analysis of the value of tests to detect samples
250 containing viable virus showed that both tests are highly sensitive. Sensitivity was 0.786
251 (0.512–0.942) and 1 (0.755–1) for SGTI-flex COVID-19 Ag and Biocredit COVID-19 Ag.
252 The control method (RT-PCR) had sensitivity of 1 (0.886–1). In turn, specificity of rapid
253 tests was significantly higher than that of RT-PCR and was 0.663 (0.557–0.758) and
254 0.674 (0.568–0.768) for SGTI-flex COVID-19 Ag and Biocredit COVID-19 Ag versus
255 0.304 (0.213–0.409) obtained for PCR. Statistically, the results of the antigen tests used
256 in the study are indistinguishable from each other (p -value = 0.4533), but differ
257 significantly from RT-PCR (p -value = 2.546×10^{-6} for SGTI-flex COVID-19 Ag, p -value =
258 1.519×10^{-8} for Biocredit COVID-19 Ag). This means that rapid tests have significantly
259 better results for the task of identifying viable SARS-CoV-2.

260 We are not aware of any other studies that analyze the value of antigen tests to
261 identify patients who excrete viable virus. Results obtained in this study require
262 confirmation using more samples from patients who excrete viable virus. In this study,

263 there were 14 samples that showed viability. It appears important to investigate to what
264 extent the results of this study will correlate with data obtained on samples from
265 asymptomatic patients. It is known that such patients contribute significantly to the
266 transmission of the virus, which in the context of our study means a higher viral load
267 and, consequently, virus viability of these patients. Further investigation will clarify this
268 issue and help to understand the value of antigen tests for the widespread detection of
269 infectious agents in the context of the COVID-19 pandemic.

270 **Conclusion**

271 This article presents the results of a study on the value of rapid antigen tests to
272 identify patients who excrete viable SARS-CoV-2. With a comparable effectiveness of
273 detection of patients excreting a viable virus, antigen tests, relative to RT-PCR, showed
274 significantly fewer false-positive results on patient samples that no longer excrete a
275 viable virus, and therefore are safe for others. This suggests that practical use of
276 antigen tests can lead to shorter isolation time and quarantine of people who are safe
277 for general public.

278 Undoubtedly, a direct comparison of the analytical characteristics of RT-PCR
279 with antigen tests is not entirely correct, since the sensitivity of RT-PCR significantly
280 exceeds the sensitivity of antigen tests, however, to identify patients excreting a viable
281 virus, the value of antigen tests, according to the result we obtained, is higher. It is
282 important to note that antigen testing does not require sophisticated equipment, trained
283 personnel and complex quality control systems, which means that the widespread use
284 of antigen tests for mass screening and detection of persons excreting the virus among
285 conditionally healthy people is potentially of great value.

286 **Materials and methods**

287 *Patients*

288 The study included patients with suspected COVID-19 admitted to the hospital on day
289 2–10 from the onset of symptoms (fever, dry cough, chest pain and discomfort,
290 shortness of breath, loss of smell and taste) and with CT signs of lung damage. Study
291 was approved by the Local ethic committee of the Moscow First Infectious Diseases

292 Hospital (the Protocol #2 dated 2021-01-22). All participants signed the written informed
293 consent to allow usage of nasal swab samples for research purposes.

294 The study included a total of 106 patients aged 28 to 95 years (mean age 67.67)
295 including 53 women (mean age 68.45) and 53 men (mean age 66.89).

296 *Sample collection and transportation*

297 Using sterile swabs and observing the necessary safety precautions, nurses of the
298 hospital collected three nasopharyngeal samples from each patient, two of which were
299 used for antigen testing. The third sample was transferred to tubes with 1 mL of
300 phosphate buffered saline (PBS). All collected materials were transferred to the
301 reference center for coronavirus infection of the Gamaleya Research Institute of
302 Epidemiology and Microbiology of the Ministry of Health of Russia cooled down to +4
303 degrees Celsius within 2 hours after collection.

304 *Antigen testing*

305 Antigen testing was done immediately after sample collection in accordance with the
306 manufacturer's instructions directly at the patient's bedside. Testing was done using two
307 commercially available rapid tests for the detection of SARS-CoV-2 antigen –
308 BIOCREDIT COVID-19 Ag (RapiGEN Inc., Korea) and SGTI-flex COVID-19 Ag
309 (Sugentech Inc., Korea).

310 *SARS-CoV-2 testing*

311 All collected samples were tested immediately after transportation. PCR amplification
312 was carried out using a one-step "SARS-CoV-2 FRT" commercial kit with catalog
313 number EA-128 (bought from N.F. Gamaleya NRCEM, Moscow, Russia). According to
314 manufacturer's information "SARS-CoV-2 FRT" kit allows to amplify a fragment from the
315 5' end region encoding the NSP1 gene (aprox. 450 to 650 nt bases upstream the 5' end
316 of SARS-CoV-2 viral genome). The protocol for qPCR-RT used in this study had been
317 described previously [29]. Briefly the conditions of the one-step RT-qPCR reaction were
318 as follows: 50°C for 15 min, 95°C for 5 min, followed by 45 cycles of 95°C for 10 s and
319 55°C for 1 min. The number of copies of viral RNA was calculated using a standard
320 curve generated by amplification of plasmid cloned DNA template fragment encoding
321 450 to 650 nt bases upstream the 5' end of SARS-CoV-2 viral genome.

322 *Virus isolation*

323 Isolation of the SARS-CoV-2 virus was performed using 293T/ACE2 cell line (with
324 stable expression of the human ACE2 receptor). Cells were cultured in DMEM medium
325 (PanEco, Russia) containing 10% FBS (HyClone, USA), 1% L-glutamine, and 1%

326 penicillin/streptomycin. 96-well plate was used for the experiment. For this,
327 nasopharyngeal secretion (100 µL) from COVID-19 patients was added to tablets.
328 Plates were incubated for 5 days. Virus-induced cytopathic effect (CPE) was then
329 assessed. Also, for samples with CPE, real-time PCR was performed to confirm that
330 CPE was caused by SARS-CoV-2 and not by other infectious agents that can cause
331 CPE.

332 *Statistical treatment of results*

333 All data were statistically treated using the methods available in different R packages.
334 McNemar's test with Edwards continual correction was used to compare the two
335 different tests. Fisher's exact test was used to analyze unrelated qualitative data.
336 Quantitative indicators were checked for normal distribution using the Shapiro–Wilk test.
337 Quantitative comparison of groups was done using the Mann–Whitney test. Confidence
338 intervals for specificity and sensitivity, as well as confidence intervals for proportions,
339 were calculated using binomial distribution with the help of Clopper–Pearson method.

340 *Conflicts of Interest*

341 The authors declare no conflicts of interest. The authors: E.V.S., N.A.K., E.V.D., M.A.N.,
342 A.E.S., D.A.O., M.A.S., A.P.T., O.A.B., V.A.G. had been supported by the Ministry of
343 Health of the Russian Federation, Government assignment number AAAA-A20-
344 120113090054-6.

345

346 **Reference**

- 347 1. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, et al. Physical
348 distancing, face masks, and eye protection to prevent person-to-person
349 transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-
350 analysis. *Lancet*. 2020;395: 1973–1987.
- 351 2. BBC News. Coronavirus “could cost global economy \$8.8tn” says ADB. In: BBC
352 News [Internet]. 15 May 2020 [cited 24 Feb 2021]. Available:
353 <https://www.bbc.com/news/business-52671992>
- 354 3. Imam N, Zaidi S, Chakraborty AR. Transmission, Prevention, and Risk Factors of
355 COVID-19 - in BREAKING DOWN COVID-19. A Living Textbook. Publication of
356 First Medicine and Global Clinical Carey Kriz, Naiyer Imam, Sarah Zaidi (Eds.)
357 Partners.2020; p.25-36.
- 358 4. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral
359 shedding and transmissibility of COVID-19. *Nat Med*. 2020;26: 672–675.

- 360 5. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented
361 infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2).
362 Science. 2020. pp. 489–493. doi:10.1126/science.abb3221
- 363 6. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and
364 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384: 403–
365 416.
- 366 7. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety
367 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:
368 2603–2615.
- 369 8. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al.
370 Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-
371 CoV-2: an interim analysis of four randomised controlled trials in Brazil, South
372 Africa, and the UK. Lancet. 2021;397: 99–111.
- 373 9. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, et al. Safety and
374 efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19
375 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
376 Lancet. 2021;397: 671–681.
- 377 10. Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR, et al. Neutralization of
378 SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2
379 vaccine-elicited sera. doi:10.1101/2021.01.27.427998
- 380 11. Muik A, Wallisch A-K, Sängler B, Swanson KA, Mühl J, Chen W, et al.
381 Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-
382 elicited human sera. Science. 2021. doi:10.1126/science.abg6105
- 383 12. Hoffmann M, Arora P, Groß R, Seidel A, Hörnich B, Hahn A, et al. SARS-CoV-2
384 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies
385 induced by infection and vaccination. doi:10.1101/2021.02.11.430787
- 386 13. Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral cultures for COVID-19
387 infectivity assessment – a systematic review (Update 4).
388 doi:10.1101/2020.08.04.20167932
- 389 14. Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, et al. Rapid,
390 point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2
391 infection. Cochrane Database Syst Rev. 2020;8: CD013705.
- 392 15. Christoff AP, Cruz GNF, Sereia AFR, Boberg DR, de Bastiani DC, Yamanaka LE,
393 et al. Swab pooling: A new method for large-scale RT-qPCR screening of SARS-
394 CoV-2 avoiding sample dilution. PLoS One. 2021;16: e0246544.
- 395 16. Lohse S, Pfuhl T, Berkó-Göttel B, Rissland J, Geißler T, Gärtner B, et al. Pooling of
396 samples for testing for SARS-CoV-2 in asymptomatic people. Lancet Infect Dis.

- 397 2020;20: 1231–1232.
- 398 17. Deka S, Kalita D, Mangla A, Shankar R. Analysis of Multi-Sample Pools in the
399 Detection of SARS-CoV-2 RNA for Mass Screening: An Indian Perspective. *Indian*
400 *J Med Microbiol.* 2020;38: 451–456.
- 401 18. Barak N, Ben-Ami R, Sido T, Perri A, Shtoyer A, Rivkin M, et al. Lessons from
402 applied large-scale pooling of 133,816 SARS-CoV-2 RT-PCR tests. *Science*
403 *Translational Medicine.* 2021. p. eabf2823. doi:10.1126/scitranslmed.abf2823
- 404 19. Website. [cited 24 Feb 2021]. Available: [[https://www.npr.org/sections/health-](https://www.npr.org/sections/health-shots/2020/12/15/946692950/fda-authorizes-first-home-coronavirus-test-that-doesnt-require-a-prescription)
405 shots/2020/12/15/946692950/fda-authorizes-first-home-coronavirus-test-that-
406 doesnt-require-a-prescription
- 407 20. Du Z, Pandey A, Bai Y, Fitzpatrick MC, Chinazzi M, Pastore Y Piontti A, et al.
408 Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a
409 modelling study. *Lancet Public Health.* 2021. doi:10.1016/S2468-2667(21)00002-5
- 410 21. Criteria for releasing COVID-19 patients from isolation. [cited 24 Feb 2021].
411 Available: [https://www.who.int/publications/i/item/criteria-for-releasing-covid-19-](https://www.who.int/publications/i/item/criteria-for-releasing-covid-19-patients-from-isolation)
412 patients-from-isolation
- 413 22. Wells CR, Townsend JP, Pandey A, Moghadas SM, Krieger G, Singer B, et al.
414 Optimal COVID-19 quarantine and testing strategies.
415 doi:10.1101/2020.10.27.20211631
- 416 23. Quilty BJ, Clifford S, Flasche S, Kucharski AJ, John Edmunds W, CMMID COVID-
417 19 Working Group. Quarantine and testing strategies in contact tracing for SARS-
418 CoV-2. doi:10.1101/2020.08.21.20177808
- 419 24. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-
420 CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and
421 infectiousness: a systematic review and meta-analysis. *The Lancet Microbe.* 2021.
422 pp. e13–e22. doi:10.1016/s2666-5247(20)30172-5
- 423 25. Munblit D, Nekliudov NA, Bugaeva P, Blyuss O, Kislova M, Listovskaya E, et al.
424 StopCOVID cohort: An observational study of 3,480 patients admitted to the
425 Sechenov University hospital network in Moscow city for suspected COVID-19
426 infection. *Clin Infect Dis.* 2020. doi:10.1093/cid/ciaa1535
- 427 26. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-
428 Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-
429 CoV-2 Tests by Time Since Exposure. *Ann Intern Med* 2020
- 430 27. Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting
431 the results. *Expert Rev Mol Diagn* 2020; 20(5): 453-4.
- 432 28. Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2

433 Infection - Challenges and Implications. N Engl J Med 2020.

434 29. Pochtovyi, A.A., Bacalin, V.V., Kuznetsova, N.A., Nikiforova, M.A., Shidlovskaya,
435 E.V., Verdiev, B.I., Milashenko, E.N., Shchetinin, A.M., Burgasova, O.A.,
436 Kolobukhina, L.V., Smetanina, S.V., Tkachuk, A.P., Gushchin, V.A., Gintsburg, A.L.
437 (2021). SARS-CoV-2 Aerosol and Surface Contamination in Health Care Settings:
438 The Moscow Pilot Study. Aerosol Air Qual. Res. 21, 200604.
439 <https://doi.org/10.4209/aaqr.200604>

